What is the first-line therapy for the treatment of diffuse large B-cell lymphoma (DLBCL) in patients who have poor left ventricular functions or are very frail?

Updated: Feb 23, 2021
  • Author: Mohammad Muhsin Chisti, MD, FACP; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

First-line therapy options for patients who have poor left ventricular function or are very frail are as follows:

  • RCEPP (rituximab, cyclophosphamide, etoposide, prednisone, procarbazine)
  • RCDOP (rituximab, cyclophosphamide, liposomal doxorubicin, vincristine, prednisone)
  • DA-EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + rituximab
  • RCEOP (rituximab, cyclophosphamide, etoposide, vincristine, prednisone)
  • RGCVP (rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!